Debra A. Goff, Pharm.D., FCCP, is Infectious Disease Specialist and founding member of the Antimicrobial Stewardship Program at The Ohio State University Wexner Medical Center (OSUWMC). She is the past-Director of the Infectious Diseases Residency program at The Ohio State University Medical Center ...

Dr Peter Jackson is Executive Director of the AMR Centre – a UK public-private partnership focused on antimicrobial resistance R&D, and an alliance member of the transatlantic CARB-X initiative.  An experienced life sciences entrepreneur, Dr Jackson is the founder of six life sciences ventures...

A board-certified internist and a Fulbright scholar, Dr. Knecht has developed insights into the health care industry through experiences in pharmaceutical entrepreneurship, life science strategy consulting, patient care and population health research. Dr. Knecht currently serves as Vice President...

Mr. Wise became Chief Executive Officer, and joined the Company’s Board of Directors, in January 2018. Mr. Wise joined Achaogen as Chief Operating Officer in 2015 and, in February 2017 he was appointed President and Chief Operating Officer. Prior to Achaogen, Mr. Wise spent 13 years at...

Nicholas Adomakoh was recently appointed Global Medical Affairs lead for Anti-infectives at Sandoz (a Novartis Division). In this role, he is responsible for the development and implementation of medical strategies that balance the need to address substantial unmet needs in the field of infectious...

Årdal has worked for 20 years on access to medicines through different sectors, including research institutes, governmental development assistance, pharmaceutical industry, pharmacy, national health service and insurance. She has worked in the U.S., U.K. and Norway. She was a member of the World...

Thierry Bernardi is the founder of BioFilm Control as well as the inventor of the BioFilm Ring Test®. He has co-authored 8 peer reviewed publications and 7 patent applications using the BioFilm Ring Test® technology. Prior to founding BioFilm Control, he held several technical, general management...

Dr. Clancy is a physician and researcher with expertise in infectious diseases.  He is tenured Associate Professor of Medicine and Director of the XDR Pathogen Lab at the University of Pittsburgh.  He conducts collaborative clinical, translational and laboratory research on issues relevant to the...

Mark has been founding and building life sciences companies in China since 1990 including most recently Phagelux which develops antibacterial products for multiple industries, particularly focusing on antibiotic resistant strains.Mark is also the co-founder and director of Haoyisheng which is a...

Dr. Estrada is the Director of Clinical Affairs at T2Biosystems. She was previously the Infectious Diseases Clinical Pharmacist for Lee Health in Ft. Myers, FL for 13 years where she served as the Co-Director of Antimicrobial Stewardship and Director of the ID Pharmacy Residency Program. In that...

Dr. Kuntal Ganguly serves as the Lead Scientist – Formulation & Development at Venus Medicine Research Center (VMRC), Venus Remedies Limited, India.With more than 12 years of active research experience in Pharmaceutical and Biopharmaceutical formulation development, including therapeutic...

Silas Holland is a Director for Global Public Policy at Merck, where he is responsible for global health policy issues in infectious disease, primarily focusing on antibiotics/antifungals.Over the past 15 years, he has worked on programs at both the community- and global-level to expand access to...

John F. Kokai-Kun, PhDVice President, Non-Clinical AffairsJohn F. Kokai-Kun, PhD is currently Vice President of Non-Clinical Affairs for Synthetic Biologics, Inc. (Rockville, MD). He received his BS in Biochemistry from Juniata College in Huntingdon, PA and his PhD in Microbiology from the...

Tom Lowery, Ph.D. has served as our Chief Scientific Officer since September 2013. Since joining our company as the first employee in February 2007, Tom has held various technical leadership roles, including assay, methods, reagents and detector development programs. By applying his extensive...

Gregory G. Mario, M.B.A. is the President and CEO of TAXIS Pharmaceuticals, Inc.  After receiving his M.B.A. in Finance and Marketing at the Fuqua School of Business, Duke University, he spent 12 years in life sciences as a sales, marketing, business development, and licensing and acquisition...

Dr. Pascal Mayer, Ph.D, CEO and CSO, is a biophysicist with a wide experience in DNA sequencing, biofilms, big data management and Artificial Intelligence algorithms development. His inventions lead to the filing of 12 patent families including the core patents behind the world's leading...

Mary Millard, M. Ed.  Mary Millard is a survivor of acute septic shock and lives with multi drug resistant Pseudomonas Aeruginosa residing in biofilm, a hospital-acquired infection she contracted during a lifesaving procedure. She now speaks to congressional panels, hospitals, infection...

Harshika Sarbajna recently assumed the role of Global Head of Anti-Infectives, Oral, for Sandoz (a Novartis Division) and is responsible for ensuring sustainable access to and promoting proper use of anti-infectives.In this role, she is also spearheading the Sandoz/Novartis wide AMR Stewardship...

Rajeev Sehgal is an experienced healthcare professional with a proven track record in building and commercializing healthcare informatics solutions. He has an undergrad degree in Computer Science and Engineering from IIT Varanasi, India and an MBA from Carnegie Mellon University, Pittsburgh. At...

Fred Turner is the Founder and CEO of Shield Diagnostics and genomics startup backed by Y Combinator and Andreessen Horowitz. Fred was named in the 2018 Forbes 30 Under 30 List, received the Thiel Fellowship in 2017 and in 2014 was named one of the Top 100 UK Practising Scientists by the UK Science ...

Evan Tzanis joined Paratek in September 2014 as Vice President of Clinical Development to oversee clinical development strategic and operational deliverables including the design/oversight of clinical trials, biometrics and regulatory affairs.  In March 2018, Evan was appointed Chief Development...

Dr. Bleasdale is the physician lead for antimicrobial stewardship and infection prevention at the University of Illinois Hospital and Health Sciences System (UIH) and is a leader in related research.  In administrative roles, she directs initiatives to reduce HAIs, infections with multidrug...

Professor Mark Bradley heads the EPSRC and MRC Centre for Doctoral Training in Optical Medical Imaging and is an ERC Advanced Grant holder.Mark has a demonstrated capacity to work, publish and patent across the boundaries with a focus on the application of the tools of chemistry with the synthesis...

Lisa Davidson, MD, serves as the Medical Director of the Atrium Health Antimicrobial Support Network and as an attending Faculty Physician in the Infectious Disease Division at Carolinas Medical Center. She graduated from the Mount Sinai School of Medicine in 1999. Dr. Davidson also attended Mount...

Barry Eisenstein received his MD from Columbia University followed by training in Internal Medicine and Infectious Diseases at the University of North Carolina. He has spent his career in academia and industry, serving as chief of the ID division at the University of Texas Health Sciences...

Dr. Hermsen is the Head of Global Antimicrobial Stewardship in Global Population Health at Merck & Co. and an Adjunct Associate Professor at the University of Nebraska Medical Center, Colleges of Pharmacy and Medicine, in Omaha, Nebraska.  Dr. Hermsen received her Doctor of Pharmacy degree from ...

Dr. Houchens is the Chief of the Antibacterials Branch within the CBRN Division of BARDA and has been with BARDA since April 2012.  His primary focus is building and managing a diverse portfolio of novel therapeutics targeting both biowarfare agents and the global threat of antimicrobial...

Patrick Keenan is the Managing Director of Prevail Partners, LLC, a life sciences investment firm focused on innovative clinical stage therapeutic, medical device and diagnostics companies. During his nine-year tenure, Prevail Partners has invested in over 30 private and public companies.  These...

Dr. Lawrence D. Kerr (Larry) is the Director of Pandemic and Emerging Threats within the Office of Global Affairs at the Department of Health and Human Services (HHS).  Dr. Kerr leads and manages the Office overseeing a broad policy portfolio including the Global Health Security Agenda...

Dr. Eili Klein is a fellow at the Center for Disease Dynamics, Economics & Policy, an Assistant Professor in the Department of Emergency Medicine in the Johns Hopkins School of Medicine, and an Assistant Professor in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public ...

Jane Knisely is a Program Officer in the Bacteriology and Mycology Branch of the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Disease, NIH, where she oversees scientific programs related to antimicrobial resistance and antibacterial drug...

Jill Massey, PharmD, MBA is the Senior Vice President for Melinta Therapeutics, Inc with responsibility for the development and leadership of the Melinta Antimicrobial Resistance Program and all Medical Affairs initiatives.  She is a senior Medical Affairs Executive with proven success in affecting ...

Board-certified Clinical Microbiologist; before coming to Merck was the Director of Clinical Microbiology at Beth Israel Medical Center in NYC. At Merck is in the Basic Research Discovery and Development group and is  part of Merck’s Antimicrobial Susceptibility Testing Development Team.

Dr. Manos Perros is President and Chief Executive Officer of Entasis Therapeutics.  Manos was central to the establishment of Entasis Therapeutics, and led talks with AstraZeneca that resulted in the creation of the new company in 2015.  Manos was Vice President of the Innovative medicines and...

Dr. Mike Salter works for AB Agri as an innovation scientist seeking out new ideas and potential product solutions for all 6 AB Agri business units. In this role he engages with Academic Institutions, Research Institutes and other businesses, usually SMEs. Mike is particularly engaged in...

Robert Sambursky, MD is one of the original founders of RPS Diagnostics, and has served various roles including Chief Executive Officer from July 2012 until June 2017, President since 2010, and Chief Medical Officer since 2008. He is an inaugural member of both the Leadership Team and Board of...

Monika Schneider is a Research Associate within the biomedical innovation team at the Duke-Margolis Center for Health Policy. Her work focuses on incentives for antimicrobial product development, value-based reimbursement policy, and payment reform for medical products.Prior to...

Dr. Ed Septimus received his medical degree from Baylor College of Medicine in Houston in 1972.  Dr. Septimus went on to complete his postgraduate training in internal medicine and infectious diseases at Baylor College of Medicine in Houston. Dr. Ed Septimus is board certified in both internal...

Dr. Ribhi Shawar currently serves as the Branch Chief at the Division of Microbiology in the Office of In vitro Diagnostic and Radiological Health (OIR) at the Center for Devices and Radiological Health (CDRH) at FDA where he specializes in the area of antimicrobial susceptibility testing and...

Dr. Sibbel recently retired from nearly 39 years of mixed veterinary practice and multiple animal health company leadership roles. Most recently, he was Executive Director of Technical Services for Merck Animal Health in the US Food Animal Business Unit. In his latest role, he was responsible for...

Jennifer Townsend, MD is an Assistant Professor in Infectious Disease (ID) at Johns Hopkins University. She directs the Antimicrobial Stewardship Program at Johns Hopkins Bayview Medical Center as well as the OPAT program for patients discharged on parenteral antibiotics. She strives to reduce...

Brian Tse is currently serving as a Health Scientist at the Biomedical Advanced Research & Development Authority (BARDA), the lead organization in the U.S. Dept. of Health & Human Services for the advanced development and acquisition of medical countermeasures for public health emergencies...

Dan Wechsler joined Melinta as President and Chief Executive Officer in November 2017 and is a seasoned pharmaceutical executive with more than 25 years of healthcare experience across multiple companies and geographies, and a proven record of strategic, operational and commercial success. His...

Founder and CEO of Forge Therapeutics Inc with over 15+ years of start-up experience in business leadership roles at Arcturus Therapeutics (private), Regulus Therapeutics (NASDAQ:RGLS), Alnylam Pharmaceuticals (NASDAQ:ALNY).  Successfully driven company growth through strategic...

Dr. LaPlante earned her Bachelor of Science in Biology at Canisius College in Buffalo, NY, and Doctor of Pharmacy and post-doctoral fellowship in infectious diseases/pharmacotherapy at the Anti-infective Research Laboratory, Wayne State University in Detroit, MI. She is currently a tenured...

Dr. Huang is the Chief Medical Officer at Motif Bio, and the former Chief Medical Officer at ContraFect Corporation. Dr. Huang has also led drug development groups in anti-infectives at Pfizer and Boehringer-Ingelheim. Dr. Huang has 15 years of clinical, academic and research experience in medicine ...

Trish Simner, PhD, D(ABMM), is an Associate Professor of Pathology at the Johns Hopkins University School of Medicine and the Director of the Medical Bacteriology and Parasitology Laboratories at the Johns Hopkins Medical Institutions. She completed her undergraduate and graduate studies at the...